ORTHOFIX MEDICAL INC. (OFIX) Q3 2025 TL;DR Summary (Period Ended September 30, 2025)
FINANCIAL HIGHLIGHTS Orthofix achieved top-line growth with Q3 Net Sales of $205.6M (up 4.6% YoY), contributing to 9-month sales of $602.4M (up 3.2% YoY). Global Orthopedics drove growth (up 10.1% in Q3), while Spinal Implants/Biologics growth decelerated substantially YTD (0.3%). Gross Margin expanded to 72.2%. The Net Loss narrowed for both the quarter (\(\\)(22.8)M\() and nine months (\)$(89.97)M\(), though the Operating Loss widened to \)$(81.9)M$ YTD due to SG&A increases. Cash flow from operations imp
...